AstraZeneca licences Luye Pharma cholesterol drug in China

Luye Pharma has granted AstraZeneca’s Chinese division exclusive rights to promote its cholesterol medicine Xuezhikang Capsules in mainland China.

The drug, made by fermenting red yeast rice, is indicated to regulate abnormal lipids in blood through decrease in total blood cholesterol, triglycerides and low-density lipoprotein cholesterol.

The drug also improves high-density lipoprotein cholesterol, as well as inhibiting atherosclerotic plaque formation, protecting vascular endothelial cells and preventing lipid deposition in the liver.

According to the terms of the agreement, Luye Pharma will retain asset and commercial sales rights, registration permits, in addition to all intellectual property and additional product-related rights.

AstraZeneca China president Leon Wang said: "Cardiovascular therapy is one of our key business areas in China, and we hope to expand the accessibility of Xuezhikang further to bring benefits to more Chinese patients.

"Xuezhikang Capsules are one of our key independently-developed medicines. The partnership with AstraZeneca will enable this highly trusted and naturally made medicine to reach more Chinese patients in need."

"Building on this partnership, we will further integrate the resources of the two sides, and apply international medical management practices to promote locally developed innovative drugs in the world markets."

Luye Pharma said in a statement that it will build on AstraZeneca’s expertise in cardiovascular space to boost the accessibility of Xuezhikang Capsules in the country.

Luye Pharma Group president Yang Rongbing said: "Xuezhikang Capsules are one of our key independently-developed medicines. The partnership with AstraZeneca will enable this highly trusted and naturally made medicine to reach more Chinese patients in need.

"The deal will also help accelerate the promotion of Xuezhikang capsules in international markets, and further strengthen Luye Pharma’s competitive advantage in the cardiovascular field."

The partners are planning to further expand the availability of Xuezhikang to other countries and regions, including the US and Europe.

Apart from mainland China, the drug is currently offered in Taiwan, China, Hong Kong, S.A.R., China, Singapore and Malaysia, among others.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.